The blood-brain barrier Choline transporter

Central Nervous System Agents in Medicinal Chemistry

Volumn 12, Issue 2, 2012, Pages 95-99

  Geldenhuys, Werner J ^a   Allen, David D ^b  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Donepezil; In situ brain perfusion; LogPS; OCT; Organic cation transporters; SLC22A

Indexed keywords

BLOOD BRAIN BARRIER CHOLINE TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; PROTEIN; UNCLASSIFIED DRUG;

ACTIVE TRANSPORT; BLOOD BRAIN BARRIER; DRUG DELIVERY SYSTEM; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 84862509741     PISSN: 18715249     EISSN: 18756166     Source Type: Journal    
DOI: 10.2174/187152412800792670     Document Type: Review

References (46)

1. Pardridge, W. M. Blood-brain barrier delivery. Drug Discov. Today, 2007, 12(1/2), 54-61.
2. Abbott, N. J.; Dolman, D. E.; Patabendige, A. K. Assays to predict drug permeation across the blood-brain barrier, and distribution to brain. Curr. Drug Metab., 2008, 9, (9), 901-910.
3. Allen, D. D.; Lockman, P. R. The blood-brain barrier choline transporter as a brain drug delivery vector. Life Sci., 2003, 73(13), 1609-1615.
4. Majumdar, S.; Mitra, A. K. Chemical modification and formulation approaches to elevated drug transport across cell membranes. Expert Opin. Drug Deliv., 2006, 3(4), 511-527.
5. Giacomini, K. M.; Huang, S. M.; Tweedie, D. J.; Benet, L. Z.; Brouwer, K. L.; Chu, X.; Dahlin, A.; Evers, R.; Fischer, V.; Hillgren, K. M.; Hoffmaster, K. A.; Ishikawa, T.; Keppler, D.; Kim, R. B.; Lee, C. A.; Niemi, M.; Polli, J. W.; Sugiyama, Y.; Swaan, P. W.; Ware, J. A.; Wright, S. H.; Yee, S. W.; Zamek- Gliszczynski, M. J.; Zhang, L. Membrane transporters in drug development. Nat. Rev. Drug Discov., 2010, 9(3), 215-236.
6. Giacomini, K. M.; Huang, S. M.; Tweedie, D. J.; Benet, L. Z.; Brouwer, K. L.; Chu, X.; Dahlin, A.; Evers, R.; Fischer, V.; Hillgren, K. M.; Hoffmaster, K. A.; Ishikawa, T.; Keppler, D.; Kim, R. B.; Lee, C. A.; Niemi, M.; Polli, J. W.; Sugiyama, Y.; Swaan, P. W.; Ware, J. A.; Wright, S. H.; Yee, S. W.; Zamek- Gliszczynski, M. J.; Zhang, L. Membrane transporters in drug development. Nat. Rev. Drug Discov., 2010, 9(3), 215-236.
7. Enerson, B. E.; Drewes, L. R. The rat blood-brain barrier transcriptome. J. Cereb. Blood Flow Metab., 2006, 26(7), 959-973.
8. Abbott, N. J., Dynamics of CNS barriers: evolution, differentiation, and modulation. Cell Mol. Neurobiol., 2005, 25(1), 5-23.
9. Brightman, M. W.; Reese, T. S. Junctions between intimately apposed cell membranes in the vertebrate brain. J. Cell Biol., 1969, 40(3), 648-677.
10. Butt, A. M.; Jones, H. C.; Abbott, N. J. Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study. J. Physiol., 1990, 429, 47-62.
11. Abbott, N. J.; Patabendige, A. A.; Dolman, D. E.; Yusof, S. R.; Begley, D. J. Structure and function of the blood-brain barrier. Neurobiol. Dis., 2010, 37(1), 13-25.
12. Pajouhesh, H.; Lenz, G. R. Medicinal chemical properties of successful central nervous system drugs. NeuroRx, 2005, 2(4), 541-553.
13. de Boer, A. G.; Gaillard, P. J. Drug targeting to the brain. Annu. Rev. Pharmacol. Toxicol., 2007, 47, 323-355.
14. de Boer, A. G.; van der Sandt, I. C.; Gaillard, P. J. The role of drug transporters at the blood-brain barrier. Annu. Rev. Pharmacol. Toxicol., 2003, 43, 629-656.
15. Pardridge, W. M. Blood-brain barrier drug targeting: the future of brain drug development. Mol. Interv., 2003, 3(2), 90-105, 51.
16. Koziara, J. M.; Lockman, P. R.; Allen, D. D.; Mumper, R. J. The blood-brain barrier and brain drug delivery. J. Nanosci. Nanotechnol., 2006, 6(9-10), 2712-2735.
17. Morgan, J. C.; Sethi, K. D. Emerging drugs for Parkinson's disease. Expert Opin. Emerg. Drugs, 2006, 11(3), 403-417.
18. Cornford, E. M.; Young, D.; Paxton, J. W.; Finlay, G. J.; Wilson, W. R.; Pardridge, W. M. Melphalan penetration of the blood-brain barrier via the neutral amino acid transporter in tumor-bearing brain. Cancer Res., 1992, 52(1), 138-143.
19. Takada, Y.; Greig, N. H.; Vistica, D. T.; Rapoport, S. I.; Smith, Q. R. Affinity of antineoplastic amino acid drugs for the large neutral amino acid transporter of the blood-brain barrier. Cancer Chemother. Pharmacol., 1991, 29(2), 89-94.
20. Takada, Y.; Vistica, D. T.; Greig, N. H.; Purdon, D.; Rapoport, S. I.; Smith, Q. R. Rapid high-affinity transport of a chemotherapeutic amino acid across the blood-brain barrier. Cancer Res., 1992, 52(8), 2191-2196.
21. Smith, Q. R.; Nagura, H.; Takada, Y.; Duncan, M. W. Facilitated transport of the neurotoxin, beta-N-methylamino-L-alanine, across the blood-brain barrier. J. Neurochem., 1992, 58(4), 1330-13337.
22. Bahadduri, P. M.; Polli, J. E.; Swaan, P. W.; Ekins, S. Targeting drug transporters - combining in silico and in vitro approaches to predict in vivo. Methods Mol. Biol., 2010, 637, 65-103.
23. Ahlin, G.; Karlsson, J.; Pedersen, J. M.; Gustavsson, L.; Larsson, R.; Matsson, P.; Norinder, U.; Bergstrom, C. A.; Artursson, P. Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. J. Med. Chem., 2008, 51(19), 5932-5942.
24. Bednarczyk, D.; Ekins, S.; Wikel, J. H.; Wright, S. H. Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol. Pharmacol., 2003, 63(3), 489-498.
25. Suhre, W. M.; Ekins, S.; Chang, C.; Swaan, P. W.; Wright, S. H. Molecular determinants of substrate/inhibitor binding to the human and rabbit renal organic cation transporters hOCT2 and rbOCT2. Mol. Pharmacol., 2005, 67(4), 1067-1077.
26. Allen, D. D.; Smith, Q. R. Characterization of the blood-brain barrier choline transporter using the in situ rat brain perfusion technique. J. Neurochem., 2001, 76(4), 1032-1041.
27. Ansell, G. B.; Spanner, S. Studies on the origin of choline in the brain of the rat. Biochem. J., 1971, 122(5), 741-750.
28. Lockman, P. R.; Mumper, R. J.; Khan, M. A.; Allen, D. D. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev. Ind. Pharm., 2002, 28(1), 1-13.
29. Devraj, K.; Klinger, M. E.; Myers, R. L.; Mokashi, A.; Hawkins, R. A.; Simpson, I. A. GLUT-1 glucose transporters in the blood-brain barrier: Differential phosphorylation. J. Neurosci. Res., 2011, 89(12), 1913-1925.
30. Jóźwiak, P.; Lipińska, A. The role of glucose transporter 1 (GLUT1) in the diagnosis and therapy of tumors. Postepy. Hig. Med. Dosw. (Online), 2012, 4(66), 165-174.
31. Lockman, P. R.; Roder, K. E.; Allen, D. D. Inhibition of the rat blood-brain barrier choline transporter by manganese chloride. J. Neurochem., 2001, 79(3), 588-594.
32. Mittapalli, R. K.; Manda, V. K.; Adkins, C. E.; Geldenhuys, W. J.; Lockman, P. R. Exploiting nutrient transporters at the blood-brain barrier to imporve brain distribution of small molecules. Ther. Deliv., 2010, 1(6), 775-784.
33. Kang, Y.S.; Lee, K.E.; Lee, N.Y.; Terasaki, T. Donepezil, tacrine and alpha-phenyl-n-tert-butyl nitrone (PBN) inhibit choline transport by conditionally immortalized rat brain capillary endothelial cell lines (TR-BBB). Arch. Pharm. Res., 2005, 28(4), 443-450.
34. Kim, M. H.; Maeng, H. J.; Yu, K. H.; Lee, K. R.; Tsuruo, T.; Kim, D. D.; Shim, C. K.; Chung, S. J. Evidence of carrier-mediated transport in the penetration of donepezil into the rat brain. J. Pharm. Sci., 2010, 99(3), 1548-1566.
35. Wooters, T. E.; Smith, A. M.; Pivavarchyk, M.; Siripurapu, K. B.; McIntosh, J. M.; Zhang, Z.; Crooks, P. A.; Bardo, M. T.; Dwoskin, L. P. BPiDI: a novel selective alpha6beta2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse. Br. J. Pharmacol., 163(2), 346-357.
36. Dwoskin, L. P.; Smith, A. M.; Wooters, T. E.; Zhang, Z.; Crooks, P. A.; Bardo, M. T. Nicotinic receptor-based therapeutics and candidates for smoking cessation. Biochem. Pharmacol., 2009, 78(7), 732-743.
37. Lockman, P. R.; Allen, D. D. The transport of choline. Drug Dev. Ind. Pharm., 2002, 28(7), 749-771.
38. van de Waterbeemd, H.; Gifford, E. ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discov., 2003, 2(3), 192-204.
39. Goodwin, J. T.; Clark, D. E. In silico predictions of blood-brain barrier penetration: considerations to keep in mind. J. Pharmacol. Exp. Ther., 2005, 315(2), 477-483.
40. Chang, C.; Ray, A.; Swaan, P. In silico strategies for modeling membrane transporter function. Drug Discov. Today, 2005, 10(9), 663-671.
41. Chang, C.; Swaan, P. W. Computational approaches to modeling drug transporters. Eur. J. Pharm. Sci., 2006, 27(5), 411-424.
42. Geldenhuys, W. J.; Lockman, P. R.; McAfee, J. H.; Fitzpatrick, K. T.; van der Schyf, C. J.; Allen, D. D. Molecular modeling studies on the active binding site of the blood-brain barrier choline transporter. Bioorg. Med. Chem. Lett., 2004, 14(12), 3085-3092.
43. Zhang, L.; Tsai, K. C.; Du, L.; Fang, H.; Li, M.; Xu, W. How to generate reliable and predictive CoMFA models. Curr. Med. Chem., 2011, 18(6), 923-930.
44. Geldenhuys, W. J.; Lockman, P. R.; Philip, A. E.; McAfee, J. H.; Miller, B. L.; McCurdy, C. R.; Allen, D. D. Inhibition of choline uptake by N-cyclohexylcholine, a high affinity ligand for the choline transporter at the blood-brain barrier. J. Drug Target, 2005, 13(4), 259-266.
45. Geldenhuys, W. J.; Lockman, P. R.; Nguyen, T. H.; van der Schyf, C. J.; Crooks, P. A.; Dwoskin, L. P.; Allen, D. D. 3D-QSAR study of bis-azaaromatic quaternary ammonium analogs at the bloodbrain barrier choline transporter. Bioorg. Med. Chem., 2005, 13(13), 4253-4261.
46. Geldenhuys, W. J.; Manda, V. K.; Mittapalli, R. K.; Van der Schyf, C. J.; Crooks, P. A.; Dwoskin, L. P.; Allen, D. D.; Lockman, P. R. Predictive screening model for potential vector-mediated transport of cationic substrates at the blood-brain barrier choline transporter. Bioorg. Med. Chem. Lett., 2010, 20(3), 870-877.